Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2015 | Targeting the survival cascade of B-cells in lymphoid malignancies

Wyndham Wilson, MD, PhD from the National Cancer Institute, Bethesda, MD talks about drugs that have been developed to indirectly target BCR, such as venetoclax (ABT-199), a Bcl-2 inhibitor; drugs targeting transcription factors, called bromodomain inhibitors, targeting MYC and NF-kappaB.